Enterohepatic bacterial infections dysregulate the FGF15-FGFR4 endocrine axis

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Romain, Guillaume ^a   Tremblay, Sarah ^a   Arena, Ellen T ^b,d   Antunes, L Caetano M ^b,e   Covey, Scott ^c   Chow, Michael T ^c,f   Finlay, B Brett ^b,c   Menendez, Alfredo ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d INSTITUT PASTEUR   (France)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f Qu Biologics Inc   (Canada)

Author keywords

Klotho; Endocrine; Enterohepatic; FGF15; FGF19; FGFR4; Infection; Listeria; Metabolism; Salmonella

Indexed keywords

CHOLESTEROL; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCOSIDASE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BETA KLOTHO GENE; BILE; BIOACCUMULATION; CHOLESTEROL LIVER LEVEL; DIGESTIVE FUNCTION; ENDOCRINE SYSTEM; FEMALE; FIBROBLAST GROWTH FACTOR 15 GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 4 GENE; GENE EXPRESSION; HEPATOBILIARY FUNCTION; HOMEOSTASIS; IN VIVO STUDY; INTESTINE; LIVER FUNCTION; MOUSE; NONHUMAN; REDUCTION; TYPHOID FEVER;

BACTERIA (MICROORGANISMS); LISTERIA; MUS; SALMONELLA;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; GASTROINTESTINAL TRACT; GENE EXPRESSION PROFILING; LISTERIOSIS; LIVER; MICE; MICE, INBRED C57BL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SALMONELLA INFECTIONS, ANIMAL;

EID: 84886383992     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-238     Document Type: Article

References (37)

1. Metabolic effects of infection on protein and energy status. Powanda MC, Beisel WR, J Nutr 2003 133 1 322S 327S 12514319
2. Defective glucose homeostasis during infection. McGuinness OP, Annu Rev Nutr 2005 25 9 35 10.1146/annurev.nutr.24.012003.132159 16011457
3. Khosla SN, Typhoyd fever. Its cause, transmission and prevention New Delhi: Atlantic Publishers 2008
4. Impact of salmonella infection on host hormone metabolism revealed by metabolomics. Antunes LC, Arena ET, Menendez A, Han J, Ferreira RB, Buckner MM, Lolic P, Madilao LL, Bohlmann J, Borchers CH, et al. Infect Immun 2011 79 4 1759 1769 10.1128/IAI.01373-10 21321075
5. Epidemiological and clinical aspects of human typhoid fever. Parry CM, Salmonella infections: clinical, immunological and molecular aspects Cambridge, New York: Cambridge University Press, Mastroeni P, Maskell D, 2006
6. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, et al. Cell Metab 2005 2 4 217 225 10.1016/j.cmet.2005.09.001 16213224
7. Physiology of FGF15/19. Jones SA, Endocrine FGFs and Klothos New York: Landes Bioscience and Springer Science, Kuro-o M, 2012 171 182
8. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Potthoff MJ, Kliewer SA, Mangelsdorf DJ, Genes Dev 2012 26 4 312 324 10.1101/gad.184788.111 22302876
9. Bile acids: regulation of synthesis. Chiang JY, J Lipid Res 2009 50 10 1955 1966 10.1194/jlr.R900010-JLR200 19346330
10. Beta-Klotho and FGF-15/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes. Sinha J, Chen F, Miloh T, Burns RC, Yu Z, Shneider BL, Am J Physiol Gastrointest Liver Physiol 2008 295 5 996 G1003 10.1152/ajpgi.90343.2008 18772362
11. Identification of a hormonal basis for gallbladder filling. Choi M, Moschetta A, Bookout AL, Peng L, Umetani M, Holmstrom SR, Suino-Powell K, Xu HE, Richardson JA, Gerard RD, et al. Nat Med 2006 12 11 1253 1255 10.1038/nm1501 17072310
12. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL, J Biol Chem 2000 275 20 15482 15489 10.1074/jbc.275.20.15482 10809780
13. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, J Clin Invest 2005 115 8 2202 2208 10.1172/JCI23076 16075061
14. Klotho and betaKlotho. Kuro-o M, Adv Exp Med Biol 2012 728 25 40 10.1007/978-1-4614-0887-1-2 22396160
15. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Lenicek M, Duricova D, Komarek V, Gabrysova B, Lukas M, Smerhovsky Z, Vitek L, Inflamm Bowel Dis 2011 17 6 1322 1327 10.1002/ibd.21502 21058331
16. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Walters JR, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW, Clin Gastroenterol Hepatol 2009 7 11 1189 1194 10.1016/j.cgh.2009.04. 024 19426836
17. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Schaap FG, van der Gaag NA, Gouma DJ, Jansen PL, Hepatology 2009 49 4 1228 1235 10.1002/hep.22771 19185005
18. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG, Am J Physiol Gastrointest Liver Physiol 2010 298 3 440 G445 10.1152/ajpgi.00322.2009 20093562
19. Distribution of the invA, -B, -C, and -D genes of Salmonella typhimurium among other Salmonella serovars: InvA mutants of Salmonella typhi are deficient for entry into mammalian cells. Galan JE, Curtiss R 3rd, Infect Immun 1991 59 9 2901 2908 1879916
20. Adoptive transfer of immunity to Listeria monocytogenes. The influence of in vitro stimulation on lymphocyte subset requirements. Bishop DK, Hinrichs DJ, J Immunol 1987 139 6 2005 2009 3114382
21. A new mathematical model for relative quantification in real-time RT-PCR. Pfaffl MW, Nucleic Acids Res 2001 29 9 45 10.1093/nar/29.9.e45 11328886
22. Salmonella infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute typhoid fever. Menendez A, Arena ET, Guttman JA, Thorson L, Vallance BA, Vogl W, Finlay BB, J Infect Dis 2009 200 11 1703 1713 10.1086/646608 19852670
23. Salmonella entry: M cells versus absorptive enterocytes. van Asten AJ, Koninkx JF, van Dijk JE, Vet Microbiol 2005 108 1-2 149 152 15885932
24. Host resistance to an intragastric infection with Listeria monocytogenes in mice depends on cellular immunity and intestinal bacterial flora. Okamoto M, Nakane A, Minagawa T, Infection and immunity 1994 62 8 3080 3085 8039875
25. Understanding how Listeria monocytogenes targets and crosses host barriers. Lecuit M, Clin Microbiol Infect 2005 11 6 430 436 10.1111/j.1469-0691. 2005.01146.x 15882192
26. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. De Gottardi A, Touri F, Maurer CA, Perez A, Maurhofer O, Ventre G, Bentzen CL, Niesor EJ, Dufour JF, Dig Dis Sci 2004 49 6 982 989 15309887
27. Regulation of the mouse organic solute transporter alpha-beta, Ostalpha-Ostbeta, by bile acids. Frankenberg T, Rao A, Chen F, Haywood J, Shneider BL, Dawson PA, Am J Physiol Gastrointest Liver Physiol 2006 290 5 912 G922 16357058
28. The role of inflammation in cholestasis: clinical and basic aspects. Kosters A, Karpen SJ, Semin Liver Dis 2010 30 2 186 194 10.1055/s-0030-1253227 20422500
29. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL, Hepatology 2010 52 2 656 666 10.1002/hep.23708 20683963
30. Therapeutic utilities of fibroblast growth factor 19. Wu X, Li Y, Expert Opin Ther Targets 2011 15 11 1307 1316 10.1517/14728222.2011.624514 21961833
31. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, et al. Endocrinology 2002 143 5 1741 1747 10.1210/en.143.5.1741 11956156
32. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, et al. Endocrinology 2004 145 6 2594 2603 10.1210/en.2003-1671 14976145
33. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. Bhatnagar S, Damron HA, Hillgartner FB, J Biol Chem 2009 284 15 10023 10033 10.1074/jbc.M808818200 19233843
34. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, et al. J Biol Chem 2010 285 8 5165 5170 10.1074/jbc.M109.068783 20018895
35. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Uriarte I, Fernandez-Barrena MG, Monte MJ, Latasa MU, Chang HC, Carotti S, Vespasiani-Gentilucci U, Morini S, Vicente E, Concepcion AR, et al. Gut 2013 62 6 899 910 10.1136/gutjnl-2012-302945 23292666
36. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F, Endocrinology 2012 153 9 4238 4245 10.1210/en.2012-1193 22778214
37. Identification and characterization of Cri1, a locus controlling mortality during Citrobacter rodentium infection in mice. Diez E, Zhu L, Teatero SA, Paquet M, Roy MF, Loredo-Osti JC, Malo D, Gruenheid S, Genes Immun 2011 12 280 290 10.1038/gene.2010.76 21326319